Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Maintenance Therapy Combined with Low-dose Etoposide in Extensive-Stage Small Cell Lung Cancer
KCT0012495Phase 2Not yet recruiting
- Sponsor
- Pusan National University Hospital
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, etoposide in small cell lung cancer (SCLC), sponsored by Pusan National University Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
atezolizumabetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on KCT0012495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012495.